Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioceramides and Niacinamide for Post-Inflammatory Hyperpigmentation in Black Women
NCT07618572Recruiting
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of nicotinamide in Post-inflammatory hyperpigmentation (PIH), sponsored by Hospital Israelita Albert Einstein. Primary endpoints: Hyperpigmentation Area Severity Scale at Week 12, Visual Assessment of Post-Inflammatory Hyperpigmentation Using Standardized Facial Photography at Week 12 and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
nicotinamide
03
Conditions
Post-inflammatory hyperpigmentation (PIH)
Beyond the preview
Go deeper on NCT07618572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618572.